Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medical Oncology | 37 | 2024 | 2321 | 4.360 |
Why?
|
Breast Neoplasms | 89 | 2024 | 21012 | 3.330 |
Why?
|
Neoplasms | 65 | 2024 | 22170 | 2.630 |
Why?
|
Informed Consent | 10 | 2022 | 1008 | 1.660 |
Why?
|
Cytochrome P-450 CYP2D6 | 8 | 2016 | 107 | 1.580 |
Why?
|
Tamoxifen | 10 | 2016 | 965 | 1.150 |
Why?
|
Quality of Life | 32 | 2024 | 13367 | 1.110 |
Why?
|
Health Expenditures | 9 | 2024 | 2366 | 1.020 |
Why?
|
Early Detection of Cancer | 6 | 2022 | 3201 | 1.000 |
Why?
|
Exercise Therapy | 10 | 2023 | 929 | 0.970 |
Why?
|
Antineoplastic Agents, Hormonal | 15 | 2024 | 1520 | 0.950 |
Why?
|
Health Care Costs | 11 | 2023 | 3242 | 0.950 |
Why?
|
Clinical Trials as Topic | 16 | 2024 | 8002 | 0.920 |
Why?
|
Biological Specimen Banks | 2 | 2019 | 783 | 0.890 |
Why?
|
Ethics Consultation | 1 | 2022 | 59 | 0.790 |
Why?
|
Biopsy | 12 | 2024 | 6766 | 0.760 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2020 | 1081 | 0.730 |
Why?
|
Music | 1 | 2023 | 245 | 0.730 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2024 | 9280 | 0.710 |
Why?
|
Medical Assistance | 2 | 2017 | 108 | 0.680 |
Why?
|
Cost of Illness | 9 | 2024 | 1936 | 0.640 |
Why?
|
Humans | 186 | 2024 | 761504 | 0.630 |
Why?
|
Therapies, Investigational | 2 | 2010 | 111 | 0.630 |
Why?
|
Tissue Banks | 1 | 2019 | 184 | 0.620 |
Why?
|
Chemotherapy, Adjuvant | 19 | 2024 | 3514 | 0.610 |
Why?
|
Mastectomy, Segmental | 6 | 2020 | 955 | 0.600 |
Why?
|
Fear | 4 | 2024 | 1476 | 0.600 |
Why?
|
Teaching Rounds | 1 | 2022 | 275 | 0.600 |
Why?
|
Mass Screening | 5 | 2022 | 5428 | 0.600 |
Why?
|
Health Care Rationing | 3 | 2021 | 437 | 0.590 |
Why?
|
Patients | 6 | 2021 | 907 | 0.570 |
Why?
|
Cost-Benefit Analysis | 10 | 2022 | 5492 | 0.520 |
Why?
|
Health Services Needs and Demand | 3 | 2020 | 1403 | 0.520 |
Why?
|
Female | 115 | 2024 | 392644 | 0.510 |
Why?
|
Exercise | 7 | 2021 | 5890 | 0.500 |
Why?
|
Drug Costs | 4 | 2019 | 1183 | 0.490 |
Why?
|
Health Knowledge, Attitudes, Practice | 8 | 2016 | 4016 | 0.480 |
Why?
|
Physician-Patient Relations | 8 | 2024 | 3249 | 0.480 |
Why?
|
Insurance, Health | 3 | 2017 | 2498 | 0.460 |
Why?
|
Survivors | 12 | 2023 | 2371 | 0.460 |
Why?
|
Nurse Practitioners | 1 | 2017 | 271 | 0.460 |
Why?
|
Patient Preference | 2 | 2019 | 924 | 0.450 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13639 | 0.450 |
Why?
|
Decision Making | 7 | 2024 | 3929 | 0.430 |
Why?
|
Biomedical Research | 8 | 2024 | 3429 | 0.420 |
Why?
|
Pharmacogenetics | 2 | 2014 | 675 | 0.410 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 623 | 0.410 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2024 | 629 | 0.410 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2009 | 132 | 0.400 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 1069 | 0.390 |
Why?
|
Tissue Extracts | 1 | 2012 | 141 | 0.390 |
Why?
|
Practice Guidelines as Topic | 8 | 2019 | 7390 | 0.390 |
Why?
|
Ethics, Medical | 3 | 2022 | 783 | 0.380 |
Why?
|
Attitude of Health Personnel | 7 | 2019 | 3889 | 0.380 |
Why?
|
Emotions | 2 | 2023 | 2739 | 0.380 |
Why?
|
Genetic Research | 1 | 2012 | 171 | 0.370 |
Why?
|
Public Opinion | 1 | 2015 | 484 | 0.370 |
Why?
|
Patient Participation | 6 | 2019 | 1444 | 0.370 |
Why?
|
Fertility | 6 | 2022 | 771 | 0.350 |
Why?
|
Mandatory Testing | 1 | 2010 | 23 | 0.350 |
Why?
|
Middle Aged | 63 | 2024 | 220895 | 0.350 |
Why?
|
Adult | 63 | 2024 | 221177 | 0.350 |
Why?
|
Databases as Topic | 1 | 2012 | 473 | 0.340 |
Why?
|
Learning | 1 | 2019 | 1740 | 0.340 |
Why?
|
Private Sector | 1 | 2013 | 398 | 0.340 |
Why?
|
Carcinoma | 2 | 2021 | 2330 | 0.340 |
Why?
|
Drug Industry | 3 | 2017 | 788 | 0.330 |
Why?
|
Perception | 2 | 2015 | 1197 | 0.330 |
Why?
|
Health Behavior | 2 | 2019 | 2643 | 0.330 |
Why?
|
Cross-Sectional Studies | 14 | 2024 | 26125 | 0.320 |
Why?
|
Mammography | 2 | 2017 | 2430 | 0.320 |
Why?
|
Off-Label Use | 1 | 2010 | 185 | 0.320 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 709 | 0.310 |
Why?
|
Aged | 49 | 2024 | 169289 | 0.310 |
Why?
|
Health Services Accessibility | 7 | 2020 | 5440 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2021 | 10209 | 0.310 |
Why?
|
Receptor, erbB-2 | 8 | 2023 | 2557 | 0.310 |
Why?
|
Health Resources | 1 | 2014 | 935 | 0.300 |
Why?
|
Urologic Neoplasms | 1 | 2012 | 314 | 0.300 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 857 | 0.290 |
Why?
|
Neoadjuvant Therapy | 6 | 2020 | 2827 | 0.280 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2012 | 942 | 0.280 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 582 | 0.270 |
Why?
|
Receptors, Estrogen | 5 | 2020 | 2208 | 0.260 |
Why?
|
Quality of Health Care | 6 | 2018 | 4330 | 0.260 |
Why?
|
Endpoint Determination | 2 | 2024 | 590 | 0.260 |
Why?
|
Self Efficacy | 3 | 2015 | 638 | 0.260 |
Why?
|
Patient Acceptance of Health Care | 3 | 2018 | 3205 | 0.250 |
Why?
|
Epidemiologic Research Design | 1 | 2009 | 368 | 0.250 |
Why?
|
Resilience, Psychological | 2 | 2024 | 788 | 0.250 |
Why?
|
Attitude | 2 | 2020 | 775 | 0.250 |
Why?
|
Oxygen Consumption | 5 | 2023 | 1866 | 0.240 |
Why?
|
Adaptation, Psychological | 7 | 2022 | 2629 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.230 |
Why?
|
Pilot Projects | 6 | 2024 | 8631 | 0.230 |
Why?
|
Medical Errors | 1 | 2012 | 1263 | 0.220 |
Why?
|
Patient-Centered Care | 2 | 2022 | 1421 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11742 | 0.220 |
Why?
|
Information Dissemination | 1 | 2012 | 1126 | 0.220 |
Why?
|
Patient Selection | 4 | 2014 | 4244 | 0.220 |
Why?
|
Cost Sharing | 2 | 2017 | 409 | 0.220 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 4243 | 0.210 |
Why?
|
Employment | 1 | 2009 | 1118 | 0.210 |
Why?
|
Research Support as Topic | 1 | 2007 | 697 | 0.210 |
Why?
|
Societies, Medical | 7 | 2019 | 3905 | 0.210 |
Why?
|
Prospective Studies | 22 | 2024 | 54425 | 0.200 |
Why?
|
Medication Adherence | 8 | 2024 | 2176 | 0.200 |
Why?
|
Socioeconomic Factors | 9 | 2021 | 7827 | 0.200 |
Why?
|
Physicians | 5 | 2016 | 4591 | 0.200 |
Why?
|
Body Composition | 1 | 2011 | 2426 | 0.190 |
Why?
|
Mastectomy | 5 | 2021 | 1822 | 0.190 |
Why?
|
Life Style | 3 | 2021 | 3917 | 0.190 |
Why?
|
Receptors, Progesterone | 3 | 2021 | 1129 | 0.190 |
Why?
|
Ethics Committees, Research | 1 | 2022 | 196 | 0.180 |
Why?
|
United States | 23 | 2024 | 72334 | 0.180 |
Why?
|
Income | 4 | 2021 | 1877 | 0.180 |
Why?
|
Camptothecin | 1 | 2024 | 591 | 0.180 |
Why?
|
Genotype | 9 | 2020 | 12990 | 0.180 |
Why?
|
Certification | 1 | 2024 | 418 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 29625 | 0.180 |
Why?
|
Feasibility Studies | 5 | 2024 | 5247 | 0.180 |
Why?
|
BRCA2 Protein | 2 | 2022 | 805 | 0.170 |
Why?
|
Data Collection | 4 | 2014 | 3322 | 0.170 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8529 | 0.170 |
Why?
|
Aged, 80 and over | 23 | 2024 | 58976 | 0.170 |
Why?
|
Publishing | 1 | 2007 | 833 | 0.170 |
Why?
|
Telemedicine | 3 | 2022 | 3051 | 0.170 |
Why?
|
Anxiety | 3 | 2023 | 4573 | 0.170 |
Why?
|
Habits | 1 | 2020 | 147 | 0.160 |
Why?
|
Social Justice | 1 | 2024 | 478 | 0.160 |
Why?
|
Neoplasm Staging | 10 | 2022 | 11121 | 0.160 |
Why?
|
Male | 28 | 2024 | 360804 | 0.160 |
Why?
|
Genomics | 4 | 2023 | 5821 | 0.160 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1008 | 0.160 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2020 | 1085 | 0.160 |
Why?
|
Resource Allocation | 1 | 2021 | 350 | 0.160 |
Why?
|
Health Status Disparities | 2 | 2012 | 1852 | 0.150 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2020 | 258 | 0.150 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1155 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 257 | 0.150 |
Why?
|
Menopause | 4 | 2017 | 1646 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 518 | 0.150 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 2693 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2021 | 1784 | 0.150 |
Why?
|
Nontherapeutic Human Experimentation | 1 | 2017 | 22 | 0.150 |
Why?
|
Healthcare Disparities | 5 | 2017 | 3358 | 0.140 |
Why?
|
Medicare | 2 | 2015 | 6770 | 0.140 |
Why?
|
Social Support | 3 | 2024 | 2171 | 0.140 |
Why?
|
Organizational Policy | 1 | 2019 | 432 | 0.140 |
Why?
|
Palliative Care | 3 | 2020 | 3598 | 0.140 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2022 | 326 | 0.140 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2024 | 946 | 0.140 |
Why?
|
Interviews as Topic | 1 | 2024 | 2696 | 0.140 |
Why?
|
Aromatase Inhibitors | 3 | 2015 | 513 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2024 | 954 | 0.140 |
Why?
|
Fatigue | 2 | 2022 | 1552 | 0.140 |
Why?
|
Patient Satisfaction | 4 | 2021 | 3461 | 0.130 |
Why?
|
Treatment Outcome | 14 | 2021 | 64680 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 646 | 0.130 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 297 | 0.130 |
Why?
|
Patient Advocacy | 2 | 2024 | 360 | 0.130 |
Why?
|
Carcinoma, Ductal | 1 | 2016 | 97 | 0.130 |
Why?
|
Health Planning | 1 | 2017 | 230 | 0.130 |
Why?
|
Communication | 5 | 2019 | 3873 | 0.130 |
Why?
|
Mind-Body Therapies | 3 | 2024 | 279 | 0.130 |
Why?
|
Diphosphonates | 2 | 2012 | 636 | 0.130 |
Why?
|
Financial Support | 2 | 2013 | 117 | 0.130 |
Why?
|
Fasting | 1 | 2022 | 1603 | 0.130 |
Why?
|
Rural Population | 2 | 2017 | 2285 | 0.130 |
Why?
|
Delivery of Health Care | 4 | 2019 | 5336 | 0.120 |
Why?
|
Breast | 2 | 2022 | 1967 | 0.120 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9420 | 0.120 |
Why?
|
Health Priorities | 1 | 2017 | 374 | 0.120 |
Why?
|
Young Adult | 14 | 2024 | 59243 | 0.120 |
Why?
|
Age Factors | 7 | 2021 | 18395 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2014 | 2319 | 0.110 |
Why?
|
Needs Assessment | 1 | 2020 | 1139 | 0.110 |
Why?
|
Stress, Psychological | 3 | 2022 | 4481 | 0.110 |
Why?
|
Organizational Affiliation | 1 | 2013 | 34 | 0.110 |
Why?
|
Qualitative Research | 1 | 2024 | 3023 | 0.110 |
Why?
|
Focus Groups | 1 | 2019 | 1413 | 0.110 |
Why?
|
Hematopoiesis | 1 | 2022 | 2049 | 0.110 |
Why?
|
Reaction Time | 1 | 2019 | 2082 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 495 | 0.100 |
Why?
|
Health Care Surveys | 2 | 2018 | 2426 | 0.100 |
Why?
|
Ethics Committees | 1 | 2012 | 51 | 0.100 |
Why?
|
Medically Uninsured | 1 | 2017 | 836 | 0.100 |
Why?
|
Exercise Test | 3 | 2014 | 2127 | 0.100 |
Why?
|
Aftercare | 1 | 2018 | 914 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2508 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15936 | 0.100 |
Why?
|
Research Design | 4 | 2024 | 6180 | 0.100 |
Why?
|
Cost Savings | 2 | 2014 | 913 | 0.100 |
Why?
|
North Carolina | 1 | 2012 | 325 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 3688 | 0.100 |
Why?
|
Culture | 1 | 2015 | 623 | 0.100 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2013 | 278 | 0.100 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2013 | 241 | 0.090 |
Why?
|
Skinfold Thickness | 1 | 2011 | 162 | 0.090 |
Why?
|
Plethysmography | 1 | 2011 | 175 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2018 | 2707 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2331 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2021 | 2775 | 0.090 |
Why?
|
Disclosure | 2 | 2014 | 748 | 0.090 |
Why?
|
Research | 2 | 2010 | 1982 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2057 | 0.090 |
Why?
|
Awareness | 1 | 2014 | 648 | 0.090 |
Why?
|
Choice Behavior | 1 | 2016 | 824 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1228 | 0.090 |
Why?
|
Family | 1 | 2021 | 3194 | 0.090 |
Why?
|
Biotransformation | 1 | 2009 | 166 | 0.080 |
Why?
|
Marital Therapy | 1 | 2009 | 44 | 0.080 |
Why?
|
Educational Status | 1 | 2017 | 2522 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1896 | 0.080 |
Why?
|
Carcinoma, Lobular | 1 | 2013 | 481 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12059 | 0.080 |
Why?
|
Cyclophosphamide | 3 | 2013 | 2218 | 0.080 |
Why?
|
Live Birth | 2 | 2023 | 511 | 0.080 |
Why?
|
Germ Cells | 2 | 2022 | 634 | 0.080 |
Why?
|
Models, Economic | 2 | 2011 | 716 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2012 | 793 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1188 | 0.080 |
Why?
|
Complementary Therapies | 1 | 2012 | 486 | 0.080 |
Why?
|
Administration, Oral | 2 | 2024 | 4021 | 0.080 |
Why?
|
Conflict of Interest | 1 | 2013 | 554 | 0.070 |
Why?
|
Risk Assessment | 8 | 2018 | 23995 | 0.070 |
Why?
|
Neoplasm Metastasis | 4 | 2024 | 4915 | 0.070 |
Why?
|
Radiation Oncology | 1 | 2014 | 563 | 0.070 |
Why?
|
Costs and Cost Analysis | 3 | 2018 | 1668 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2023 | 80636 | 0.070 |
Why?
|
Quality Improvement | 1 | 2022 | 3801 | 0.070 |
Why?
|
Human Experimentation | 1 | 2007 | 123 | 0.070 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1792 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2022 | 1036 | 0.070 |
Why?
|
Electric Impedance | 1 | 2011 | 757 | 0.070 |
Why?
|
Logistic Models | 4 | 2017 | 13255 | 0.070 |
Why?
|
Cohort Studies | 6 | 2024 | 41487 | 0.070 |
Why?
|
Imidazoles | 1 | 2012 | 1180 | 0.070 |
Why?
|
Caregivers | 1 | 2018 | 2237 | 0.070 |
Why?
|
Vaccination | 2 | 2018 | 3384 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1998 | 0.070 |
Why?
|
Communicable Diseases | 1 | 2014 | 875 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2012 | 1475 | 0.060 |
Why?
|
Carmustine | 1 | 2005 | 138 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2007 | 641 | 0.060 |
Why?
|
Patient Care Team | 2 | 2016 | 2521 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39106 | 0.060 |
Why?
|
Health Surveys | 1 | 2015 | 4061 | 0.060 |
Why?
|
Survival Analysis | 2 | 2008 | 10090 | 0.060 |
Why?
|
Guideline Adherence | 2 | 2012 | 2220 | 0.060 |
Why?
|
Premenopause | 1 | 2009 | 1039 | 0.060 |
Why?
|
Mental Health | 1 | 2019 | 3250 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2011 | 4853 | 0.060 |
Why?
|
Drug Approval | 1 | 2012 | 814 | 0.060 |
Why?
|
Health Personnel | 1 | 2018 | 3335 | 0.060 |
Why?
|
Ovary | 1 | 2009 | 959 | 0.060 |
Why?
|
Mutation | 4 | 2023 | 30052 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7407 | 0.060 |
Why?
|
Survival Rate | 4 | 2016 | 12725 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2012 | 1051 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6863 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 106 | 0.060 |
Why?
|
Consensus | 1 | 2014 | 3123 | 0.060 |
Why?
|
Authorship | 1 | 2007 | 284 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3778 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1522 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2021 | 5146 | 0.060 |
Why?
|
Adolescent | 8 | 2024 | 88319 | 0.050 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1664 | 0.050 |
Why?
|
Walking | 1 | 2010 | 1198 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5671 | 0.050 |
Why?
|
Probability | 1 | 2008 | 2477 | 0.050 |
Why?
|
Phenotype | 3 | 2020 | 16591 | 0.050 |
Why?
|
Risk Factors | 7 | 2022 | 74206 | 0.050 |
Why?
|
Patient Care | 1 | 2007 | 622 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 398 | 0.050 |
Why?
|
Pregnancy | 5 | 2024 | 29874 | 0.050 |
Why?
|
Phthalazines | 1 | 2024 | 383 | 0.050 |
Why?
|
Postmenopause | 1 | 2010 | 2513 | 0.050 |
Why?
|
Pregnancy Outcome | 2 | 2023 | 2921 | 0.050 |
Why?
|
Time Factors | 4 | 2020 | 39967 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2023 | 307 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 12 | 0.050 |
Why?
|
North America | 1 | 2024 | 1276 | 0.040 |
Why?
|
Reference Values | 1 | 2008 | 4920 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2005 | 2115 | 0.040 |
Why?
|
Advisory Committees | 2 | 2016 | 787 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 791 | 0.040 |
Why?
|
Cisplatin | 1 | 2005 | 1651 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2022 | 20098 | 0.040 |
Why?
|
Bipolar Disorder | 1 | 2016 | 5092 | 0.040 |
Why?
|
Pharmacies | 1 | 2021 | 169 | 0.040 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 276 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11669 | 0.040 |
Why?
|
Oxygen | 1 | 2010 | 4227 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 345 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 318 | 0.040 |
Why?
|
Patient Compliance | 2 | 2021 | 2690 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1600 | 0.040 |
Why?
|
Health Promotion | 1 | 2010 | 2214 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 899 | 0.040 |
Why?
|
Lung | 1 | 2016 | 10000 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 422 | 0.040 |
Why?
|
Pregnancy Rate | 1 | 2020 | 648 | 0.040 |
Why?
|
Prescription Fees | 1 | 2018 | 153 | 0.030 |
Why?
|
Insurance Coverage | 2 | 2018 | 1940 | 0.030 |
Why?
|
Doxorubicin | 2 | 2013 | 2224 | 0.030 |
Why?
|
Anthracyclines | 1 | 2018 | 284 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1993 | 0.030 |
Why?
|
Immunotherapy | 1 | 2012 | 4652 | 0.030 |
Why?
|
Genetic Testing | 1 | 2009 | 3537 | 0.030 |
Why?
|
Heterozygote | 1 | 2022 | 2787 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6346 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2025 | 0.030 |
Why?
|
Body Image | 1 | 2020 | 638 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7581 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2927 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12463 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2880 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1089 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 678 | 0.030 |
Why?
|
Odds Ratio | 2 | 2020 | 9646 | 0.030 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2014 | 48 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2013 | 22176 | 0.030 |
Why?
|
Psychotherapy | 1 | 2023 | 1647 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10766 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1993 | 228 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 532 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 856 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1993 | 287 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2016 | 601 | 0.030 |
Why?
|
Placebos | 1 | 2017 | 1667 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12690 | 0.030 |
Why?
|
Virus Diseases | 1 | 2018 | 718 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 961 | 0.030 |
Why?
|
Depression | 2 | 2023 | 8124 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2016 | 764 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2020 | 6228 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2348 | 0.020 |
Why?
|
Lymphedema | 1 | 2018 | 525 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2004 | 3575 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1858 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2915 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4618 | 0.020 |
Why?
|
Behavior | 1 | 2014 | 541 | 0.020 |
Why?
|
Mammaplasty | 1 | 2021 | 1239 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2018 | 1530 | 0.020 |
Why?
|
Cost Control | 1 | 2013 | 628 | 0.020 |
Why?
|
Health Policy | 2 | 2011 | 2684 | 0.020 |
Why?
|
Tumor Burden | 1 | 2017 | 1893 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2684 | 0.020 |
Why?
|
Comprehension | 1 | 2016 | 621 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 14031 | 0.020 |
Why?
|
Postoperative Care | 1 | 2017 | 1468 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2018 | 1390 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1705 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 2898 | 0.020 |
Why?
|
Cognition | 1 | 2007 | 6990 | 0.020 |
Why?
|
Incidence | 1 | 2008 | 21353 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2014 | 644 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14605 | 0.020 |
Why?
|
Health Services Misuse | 1 | 2011 | 244 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15266 | 0.020 |
Why?
|
Genes | 1 | 1993 | 1823 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2917 | 0.020 |
Why?
|
Piperazines | 1 | 2019 | 2523 | 0.020 |
Why?
|
Sick Role | 1 | 2009 | 229 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1150 | 0.020 |
Why?
|
Physical Fitness | 1 | 2013 | 743 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2928 | 0.020 |
Why?
|
Developing Countries | 1 | 2021 | 2885 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2019 | 3466 | 0.020 |
Why?
|
Standard of Care | 1 | 2012 | 551 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1386 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9326 | 0.020 |
Why?
|
Beneficence | 1 | 2007 | 54 | 0.020 |
Why?
|
Australia | 1 | 2011 | 1250 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8830 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2013 | 836 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 16981 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2875 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5073 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1993 | 1111 | 0.020 |
Why?
|
Child | 3 | 2022 | 80153 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15500 | 0.020 |
Why?
|
Cardiovascular System | 1 | 2014 | 834 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2024 | 4575 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4575 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2735 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3879 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 17904 | 0.020 |
Why?
|
Stroke Volume | 1 | 2018 | 5496 | 0.010 |
Why?
|
Europe | 1 | 2011 | 3422 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5305 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1886 | 0.010 |
Why?
|
Health Services Research | 1 | 2011 | 1812 | 0.010 |
Why?
|
Education, Medical | 1 | 1995 | 1725 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2016 | 3728 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2016 | 3600 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26198 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2013 | 2645 | 0.010 |
Why?
|
Goals | 1 | 2007 | 711 | 0.010 |
Why?
|
Health Care Reform | 1 | 2011 | 1247 | 0.010 |
Why?
|
Curriculum | 1 | 1995 | 3743 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2013 | 3113 | 0.010 |
Why?
|
Alzheimer Disease | 2 | 1993 | 8599 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12974 | 0.010 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3708 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4431 | 0.010 |
Why?
|
Electrocardiography | 1 | 2014 | 6377 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3522 | 0.010 |
Why?
|
Motivation | 1 | 2009 | 2006 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 12795 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5315 | 0.010 |
Why?
|
Hospitalization | 1 | 2016 | 10723 | 0.010 |
Why?
|
Diet | 1 | 2014 | 8075 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9610 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13380 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 1993 | 441 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1993 | 2341 | 0.000 |
Why?
|
Genetic Markers | 1 | 1993 | 2601 | 0.000 |
Why?
|
Pedigree | 1 | 1993 | 4542 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1993 | 4615 | 0.000 |
Why?
|
Models, Biological | 1 | 1993 | 9469 | 0.000 |
Why?
|